Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IDEAYA Biosciences (IDYA) EBT (2020 - 2025)

Historic EBT for IDEAYA Biosciences (IDYA) over the last 6 years, with Q4 2025 value amounting to -$94.6 million.

  • IDEAYA Biosciences' EBT rose 3438.93% to -$94.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$197.1 million, marking a year-over-year increase of 3970.52%. This contributed to the annual value of -$159.3 million for FY2025, which is 5127.67% up from last year.
  • According to the latest figures from Q4 2025, IDEAYA Biosciences' EBT is -$94.6 million, which was up 3438.93% from $108.5 million recorded in Q3 2025.
  • In the past 5 years, IDEAYA Biosciences' EBT registered a high of $108.5 million during Q3 2025, and its lowest value of -$144.1 million during Q4 2024.
  • Its 5-year average for EBT is -$31.1 million, with a median of -$26.4 million in 2022.
  • Its EBT has fluctuated over the past 5 years, first tumbled by 517969.7% in 2023, then surged by 26212.76% in 2025.
  • IDEAYA Biosciences' EBT (Quarter) stood at -$18.4 million in 2021, then crashed by 43.95% to -$26.4 million in 2022, then plummeted by 58.52% to -$41.9 million in 2023, then plummeted by 243.87% to -$144.1 million in 2024, then skyrocketed by 34.39% to -$94.6 million in 2025.
  • Its last three reported values are -$94.6 million in Q4 2025, $108.5 million for Q3 2025, and -$144.1 million during Q4 2024.